ESR1 and breast carcinoma: Using neoadjuvant therapy pretreatment breast cancer data with known treatment outcome and receptor status (estrogen receptor and HER2), we show that iPANDA is capable of producing highly robust sets of pathway markers, which can be further used for stratification of samples into responder and non-responder groups.